商务合作
动脉网APP
可切换为仅中文
The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, alongside existing investors Bioqube Ventures, Korys and Novo Holdings
最终交割由 Ackermans & van Haaren 领投,新投资者 AbbVie Ventures 和 M Ventures 参与投资,现有投资者 Bioqube Ventures、Korys 和 Novo Holdings 也继续跟投。
Funds will take first development candidate COM002 into the clinic, advance a second program into IND-enabling development and expand the BiCE™ pipeline
资金将推动首个开发候选药物 COM002 进入临床试验,推进第二个项目进入支持新药临床试验申请(IND)的开发阶段,并拓展 BiCE™ 产品管线
Michael Rosenzweig (AbbVie Ventures), Charlotte Kremers (M Ventures) and Lenny Van Steenhuyse (Ackermans & van Haaren) join the Board of Directors
Michael Rosenzweig(艾伯维风投)、Charlotte Kremers(M Ventures)和 Lenny Van Steenhuyse(Ackermans & van Haaren)加入董事会
COPENHAGEN, Denmark, Nov. 17, 2026 (GLOBE NEWSWIRE) --
丹麦哥本哈根,2026年11月17日(环球新闻社)--
Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, today announced the completion of a $60 million (€54 million) seed financing round to advance its pipeline of complement-powered immune engagers toward the clinic. The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, and existing investors Bioqube Ventures, Korys and Novo Holdings..
Commit Biologics(“Commit”)是一家开创补体驱动免疫衔接器的生物技术公司,今日宣布完成6000万美元(5400万欧元)的种子轮融资,以推动其补体驱动免疫衔接器产品管线向临床阶段迈进。本轮融资的最终关闭由Ackermans & van Haaren领投,新投资者AbbVie Ventures和M Ventures参与投资,现有投资者Bioqube Ventures、Korys和Novo Holdings也继续跟投。
Proceeds from the financing will support the completion of IND-enabling activities and IND filing for COM002, Commit’s first development candidate, which was announced last week. COM002 is a dual-targeting Bispecific Complement Engager (BiCE™) molecule designed for targeted immune cell depletion, developed for patients with cancer and autoimmune disease.
融资所得将用于支持完成使能新药临床试验申请(IND)的活动,并提交Commit公司首个开发候选药物COM002的IND申请;该候选药物于上周公布。COM002是一种双靶向双特异性补体结合分子(BiCE™),旨在实现靶向免疫细胞清除,面向癌症和自身免疫性疾病患者开发。
Additionally, the financing will advance a second program into IND-enabling development and expand Commit’s BiCE™ pipeline..
此外,这笔融资还将推动第二个项目进入支持新药临床试验申请(IND)的开发阶段,并扩大 Commit 公司的 BiCE™ 产品管线。
“Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy,”.
“Commit 的创立基于一个简单的理念:补体作为我们免疫系统中最强大的组成部分之一,可以被定向引导以攻击病变细胞。借助这笔融资,我们将推动首款不依赖 T 细胞发挥作用的同类首创免疫衔接器 COM002 进入临床研究,并为补体驱动的免疫衔接器成为免疫治疗的新支柱奠定基础。”
said Dr. Thomas L. F. Montgomery Andresen, CEO of Commit Biologics
Commit Biologics 首席执行官托马斯·L·F·蒙哥马利·安德森博士表示
.
。
He added: “Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team.”
他补充道:“看到我们的首个开发候选项目获得如此强大的财务和战略投资者群体的支持,是整个团队的骄傲时刻。”
Charlotte Kremers, Principal at M Ventures, said
M Ventures 主管 Charlotte Kremers 表示
: “Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.”
“补体系统是免疫系统中最强大的效应机制之一,但在药物开发中尚未得到充分利用。Commit公司使其在标准抗体中具备可编程性,从而为开发在不同适应症中具有差异化疗效和安全性特征的药物开辟了道路。”
Lenny Van Steenhuyse, Investment Manager at Ackermans & van Haaren, added
Ackermans & van Haaren 的投资经理 Lenny Van Steenhuyse 补充道
: “We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realize the full potential of the BiCE™ platform.”.
“我们坚信,基于在靶向细胞清除方面极具说服力的临床前数据,Commit 公司的创新药物平台有望开创免疫治疗的新范式。Ackermans & van Haaren 很荣幸支持 Commit 团队,并领投此次融资,以充分释放 BiCE™ 平台的全部潜力。”
For more information, please contact:
如需更多信息,请联系:
Optimum Strategic Communications
奥普蒂姆战略传播
Nick Bastin, Stephen Adams, Aoife Minihan
尼克·巴斯汀,斯蒂芬·亚当斯,奥伊菲·米尼汉
Tel: +44 (0) 204 566 8543
电话:+44 (0) 204 566 8543
Email: commit@optimumcomms.com
电子邮件:commit@optimumcomms.com
About the BiCE™ platform
关于 BiCE™ 平台
Commit’s proprietary BiCE™ platform turns IgG antibodies into complement-powered immune engagers. BiCE™ antibodies are designed to recruit the complement protein C1q to induce rapid and selective elimination of targeted diseased cells through a T cell-independent mechanism. The platform taps into one of nature’s most ancient defense mechanisms, while retaining the properties of a conventional IgG antibody. .
Commit公司专有的BiCE™平台将IgG抗体转化为由补体驱动的免疫介导分子。BiCE™抗体旨在招募补体蛋白C1q,通过非T细胞依赖机制快速、选择性地清除靶向的病变细胞。该平台利用了自然界最古老的防御机制之一,同时保留了传统IgG抗体的特性。
About Commit Biologics
关于 Commit Biologics
Commit Biologics is developing complement-powered immune engagers, a new class of immunotherapies for autoimmune disease, oncology and beyond. Founded as a spin-out from Aarhus University, a long-standing internationally recognized hub for complement research, Commit is today based in Copenhagen and Aarhus.
Commit Biologics 正在开发基于补体系统的免疫衔接分子,这是一类用于自身免疫性疾病、肿瘤学及其他领域的全新免疫疗法。作为从奥胡斯大学分拆成立的公司,Commit 依托该校长期作为国际公认的补体研究中心的优势,目前总部位于哥本哈根和奥胡斯。
The company is backed by Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. .
该公司由 Ackermans & van Haaren、AbbVie Ventures、M Ventures、Bioqube Ventures、Korys 和 Novo Holdings 支持。
www.commitbio.com
www.commitbio.com